View Pricing

List Price


APA Members


20% off

APA Resident-Fellow Members


25% off

Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders

Edited by Uriel Halbreich, M.D., and Stuart A. Montgomery, M.D.

  • ISBN 978-1-58562-821-6
  • Item #62821


Our limited knowledge of the pathophysiology underlying mood disorders contrasts sharply with the efficacy of the treatment modalities developed over the past decades. There has been an explosion of new antidepressant and anxiolytic medications, as well as mood stabilizers and compounds that aim to improve cognition. Although treatment success is still not optimal, pharmacotherapy for mood disorders and cognitive disorders is effective and is improving.

Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders takes a critical look at the medications available for treating mood, anxiety and cognitive disorders; their relevance to pathobiology and underlying mechanisms; and their limitations. Its 90 distinguished contributors, many of them pioneers in the development of treatment modalities, provide background and rationale in understanding the underlying mechanisms of frontline treatments for these disorders. This book reviews

  • Effective new alternatives in mood stabilizers and antidepressant interventions
  • Advances in the study of the pathobiology of anxiety disorders as well as available treatment choices, including anxiolytic medications
  • Several treatment approaches to dementia and other age-related cognitive impairments
  • Gender differences in the treatment of depression and anxiety and the different responses to pharmacotherapy
  • New treatments for social phobia and pharmacological strategies for cognitive disorders

Providing both a broad overview and detailed reviews of pharmacotherapy, this resource is essential reading for any practitioner who wants to understand the rationale and background for the drugs he or she prescribes and to assess medications that are currently under development. It is a great reference and ancillary text for students and residents during their clinical years.


Section I: Overviews
Chapter 1. Pharmacotherapy for mood, anxiety, and cognitive disorders: An overview
Chapter 2. Current theories on the pathophysiology of mood disorders
Chapter 3. Pharmacological validity of diagnostic separation
Chapter 4. Signal amplification in psychiatric diagnosis: Therapeutic implications
Chapter 5. Gender differences in treatment of depression and anxiety
Section II: Mood Stabilizers
Chapter 6. Carbamazepine and nimodipine in refractory bipolar illness: Efficacy and mechanisms
Chapter 7. Mechanisms of action of lithium in bipolar illness
Chapter 8. Clinical efficacy of valproate in bipolar illness: Comparisons and contrasts with lithium
Chapter 9. Therapeutic potential of inositol treatment in depression, panic, dementia, and lithium side effects
Chapter 10. Electroconvulsive therapy: Current practice and future directions
Chapter 11. Antidepressant and mood stabilization effects potential of transcranial magnetic stimulation
Section III: Antidepressants
Chapter 12. Changing targets of antidepressant therapy: Serotonin and beyond
Chapter 13. New emerging serotonergic antidepressants
Chapter 14. Dopamine receptors and antidepressant development
Chapter 15. Noradrenergic and other new antidepressants
Chapter 16. Sleep in depression and the effects of antidepressants on sleep
Chapter 17. Hormonal interventions as antidepressants or adjunct therapy: Treatment implications
Chapter 18. Mechanisms and management of treatment-resistant depression
Chapter 19. Treatment of psychotic depression
Chapter 20. Antidepressant maintenance medications
Section IV: Anxiolytics
Chapter 21. Overview of new anxiolytics
Chapter 22. Interactions between physiological, hormonal, and environmental determinants: The anxiety model
Chapter 23. Serotonin-specific anxiolytics: Now and in the future
Chapter 24. Serotonergic treatments for panic disorder
Chapter 25. New treatments for social phobia
Chapter 26. Why a peptide as an anxiolytic?
Chapter 27. Cholecystokinin antagonists in panic and anxiety disorders
Chapter 28. Neurosteroids
Chapter 29. Nonbenzodiazepine anxiolytics acting on the GABA receptor
Chapter 30. Treatment of obsessive-compulsive disorder: From theory to practice
Chapter 31. New approaches to treatment-refractory obsessive-compulsive disorder
Section V: Cognition and Dementia
Chapter 32. Pharmacological strategies for cognitive disorders: An overview
Chapter 33. Cholinergic approaches to cognition and dementia
Chapter 34. Serotonin mechanisms and cognition
Chapter 35. Nicotinic cholinergic approaches to cognitive enhancement in the dementias

About the Authors

Uriel Halbreich, M.D., is Professor of Psychiatry, Research Professor of Gynecology and Obstetrics, and Director of Biobehavioral Research at the State University of New York at Buffalo.

Stuart A. Montgomery, M.D., is Professor of Psychiatry in the Department of Pharmacology at St. Mary's Hospital Medical School in London, England.

What seems to set this book apart for many is the critical approach taken by the authors regarding pros and cons of the various treatments. In that regard, the book is refreshing and, I think, very useful for practitioners and researchers in the targeted areas of mood anxiety and cognitive disorders.—Journal of Clinical Psychiatry

Summarizing the pharmacotherapy of mood, anxiety and cognitive disorders in one volume is a tall order. Keeping the material up-to-date and achieving the right mix of theory and practice is even more difficult. To a large extent, the editors of this volume have achieved these goals, and for that they are to be commended.—Psychiatric Times, 12/1/2000

This is a wonderful book about psychopharmacology and pharmacological treatment methods of mood, anxiety, and cognitive disorders. It is also a rich source of references. I highly recommend it.—Doody’s Health Sciences Book Review Journal

Related Products

Become an APA Member
Join Now